{"title":"抗癌药物组合，所有可能性的研究","authors":"D. Lu, Chen Eh, Tingren Lu, Hong-ying Wu, J. Ding","doi":"10.4172/2167-1052.1000E138","DOIUrl":null,"url":null,"abstract":"Most cancer therapies are seldom effective by using single anticancer drug therapeutics based on multiple tumor genetic alterations and molecular abnormalities. Drug combinations are commonly practiced in clinics. Yet, anticancer drug combination utilities need to transform from empirical to science-guided enterprises. This editorial offers the background knowledge of drug combination therapies by mathematical enquiry.","PeriodicalId":7385,"journal":{"name":"Advances in Pharmacoepidemiology and Drug Safety","volume":"9 1","pages":"1-2"},"PeriodicalIF":0.0000,"publicationDate":"2016-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"8","resultStr":"{\"title\":\"Anticancer Drug Combinations, Studies for All Possibilities\",\"authors\":\"D. Lu, Chen Eh, Tingren Lu, Hong-ying Wu, J. Ding\",\"doi\":\"10.4172/2167-1052.1000E138\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Most cancer therapies are seldom effective by using single anticancer drug therapeutics based on multiple tumor genetic alterations and molecular abnormalities. Drug combinations are commonly practiced in clinics. Yet, anticancer drug combination utilities need to transform from empirical to science-guided enterprises. This editorial offers the background knowledge of drug combination therapies by mathematical enquiry.\",\"PeriodicalId\":7385,\"journal\":{\"name\":\"Advances in Pharmacoepidemiology and Drug Safety\",\"volume\":\"9 1\",\"pages\":\"1-2\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2016-01-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"8\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Advances in Pharmacoepidemiology and Drug Safety\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4172/2167-1052.1000E138\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Pharmacoepidemiology and Drug Safety","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4172/2167-1052.1000E138","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Anticancer Drug Combinations, Studies for All Possibilities
Most cancer therapies are seldom effective by using single anticancer drug therapeutics based on multiple tumor genetic alterations and molecular abnormalities. Drug combinations are commonly practiced in clinics. Yet, anticancer drug combination utilities need to transform from empirical to science-guided enterprises. This editorial offers the background knowledge of drug combination therapies by mathematical enquiry.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
